We are proud of the successful entry of our DeepFX hand-piece into the Japanese market. Completing this extensive approval process confirms our position as a global leader in aesthetic laser technologies
Valley Lee, MD (Vocus) February 2, 2010
Japan’s Ministry of Health, Labor and Welfare (M.H.L.W.) has approved the company’s DeepFX hand-piece for the Lumenis UltraPulse® CO2 laser in Japan. Known for its comprehensive approval process, the M.H.L.W. approval of the DeepFX hand-piece further substantiates Lumenis’ global leadership as the premier developer and manufacturer of pulsed CO2 laser technology.
“We are proud of the successful entry of our DeepFX hand-piece into the Japanese market. Completing this extensive approval process confirms our position as a global leader in aesthetic laser technologies,” says Mr. Dov Ofer, Lumenis’ Chief Executive Officer. “We are delighted to be the key innovator in this space, leveraging our expertise in pulsed CO2 laser technology to provide industry-leading outcomes,” added Mr. Ofer.
The Premier Pulsed Fractional CO2 Laser
"DeepFX Fractional Treatment with the Lumenis UltraPulse CO2 laser reduces the risk of complications such as PIH in pre-treated Asian patients with darker skin tones and produces impressive treatment results," commented Dr. Gordon H. Sasaki, M.D., F.A.C.S., former president of the Japanese American Medical Association for Southern California and Honorary Member of the Japanese Society for Plastic Surgery. "Lumenis' UltraPulse CO2 laser's power and single-pass performance means the least time on tissue, improving the experience of both patient and physician by significantly reducing the risk of complications and PIH for darker Asian skin types and by minimizing downtime,” stated Dr. Sasaki.
Receiving national acclaim on US news shows, including ABC's "20/20" and NBC's "Today," Miami dermatologist Jill Waibel, M.D. used the DeepFX hand-piece as part of the treatment to improve the appearance of burn scars, as well as increase overall flexibility and mobility in the scarred areas of the Berns triplets. “The sisters received treatments on their faces, arms and chest, and within a week they saw dramatic improvements,” says Dr. Waibel. “These results are common with the DeepFX hand-piece, which is why it’s my preferred treatment for burn scars.”
“Lumenis can now offer the unmatched pulsed CO2 laser technology of our DeepFX hand-piece to physicians in Japan, providing them with one of the most advanced pulsed CO2 laser solutions for their practices,” said Mr. Robert Mann, General Manager of Lumenis Aesthetics. “Superior in the treatment of scarred and burned skin, physicians in Japan now have access to a pulsed CO2 laser solution that greatly reduces the risk of complications in virtually every skin type and ethnicity,” added Mr. Mann.
About Lumenis’ UltraPulse CO2 Laser
The DeepFX hand-piece is powered by Lumenis’ UltraPulse CO2 laser, the most powerful fractional laser on the market, delivering six times more energy (240 watts of power to tissue) than any other CO2 laser device. Lumenis’ unique pulsed delivery equates to speed and the least time spent on tissue. DeepFX with UltraPulse CO2 laser continues to lead the industry by limiting the damage delivered to the dermis, resulting in minimal downtime and a lower risk of complications.
About Lumenis’ CO2 Laser Technology
Since 1966, Lumenis has been dedicated to engineering, manufacturing and distributing the world’s most advanced laser and intense-pulsed light systems. Lumenis holds more than 160 patents, on which much of the laser industry rests. UltraPulse technology was introduced nearly two decades ago, proving itself with over 34 FDA-cleared indications. The gold standard of CO2 lasers, UltraPulse has been referenced in over 90 peer-reviewed publications. With its long history of fractional capabilities, UltraPulse continues to lead the way in fractional resurfacing.
Lumenis, the world’s largest medical laser company, is a global developer, manufacturer and distributor of laser, light-based and radiofrequency devices for surgical, aesthetic and ophthalmic applications, with more than 800 employees worldwide. Lumenis has over 250 patents, over 75 FDA clearances, an installed base of over 80,000 systems and presence in over 100 countries. Lumenis endeavors to bring the finest state of the art technology products to the market, fulfilling the highest standards of excellence, quality and reliability, delivering premium value and service to its customers. Lumenis’ name is derived from the Latin meaning “Light of Life”, highlighting the light which is the basis of our technologies used to enhance life. For more information about Lumenis and its products, please go to: http://www.lumenis.com.
For further information contact:
Director of Corporate Communications
Lumenis and its logo are trademarks or registered trademarks of the Lumenis Group of Companies.
Certain statements and information in this press release may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections of results of operations or of financial condition and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. Forward-looking statements are often characterized by the use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue,” “believe,” “should,” “intend,” “project” or other similar words, but are not the only way these statements are identified. We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements may be found in our most recent Annual Report on Form 20-F, including the section therein entitled “Risk Factors”, as well in our reports on Form 6-K, filed with the Securities and Exchange Commission.